INTRODUCTION
Gonorrhoea is still one of the commonest sexually transmitted diseases in the western hemisphere. There are 2 main different types of gonorrhoea; uncomplicated gonorrhoea with infe~tion.of the urethra, cervix, rectum, pharynx or conJ?n~tiva~nd complicated gonorrhoea, when there 1S infection beyond the portal of entry. Uncompli~~t~d gonorrhoea, particularly urethritis and cervicitis, is much more common. Today, all types of u.ncomplicated gonorrhoea can be treated wi~h a smgle dose of an effective antibiotic. Recent guidelines for the treatment of gonococcal infection recommend either third generation cephalosporins, especially ceftriaxone and cefixime or sec~nd generation fluoroquinolones. Third generation cephalosporins and the new quinolones are h~gh~y effective against Neisseria gonorrhoeae. Th1S 1S especially important in the eradication of strains ith chromosome or plasmid-mediated r~sistance, in particular penicillinase-producing strains.
We have reviewed the recent literature in order to aSSess the role of various antibiotics in the treatment of uncomplicated gonorrhoea.
RECENT CHANGES IN THERAPỸ~t
he last few years the treatm~nt ?f gon~~al Infection has changed. Until the eighties pemcillm was the antibiotic of choice in the treatment of gonorrhoea. It was recommended by the Centers for D· h . . ti 710 iseass Control and many ot er insntu ons-: . In the mid seventies the first penicillinase or -lactamase-producing strains were encountered. Those strains were especially common in the far~ast and in the USA18. In Europe~-lactamase-producmg strains were mainly found in the United~gd~m and in the Netherlandslv-", In the late eighties penicillin resistant strains had spread rapidly.
Correspondence to: Prof Dr H C Korting, Department of Dermatology and Venerology, Frauenlobstr. 9-11, 0-80337 Munchen, Federal Republic of Germany In Germany e.g., in our centre in 1989 10%~ lactamase-producing strains were found 2S • In the seventies tetracycline-resistant strains appeared and physicians in the USA observed that single dose treatment wit~tetracyclin.e co~l~no longer eradicate the bactena totally. WIth minimal inhibitory concentration (MIC) values of 2 gIl or 4 gIlrespectively a bacteriologicalcure by methacydine or doxycycline was no longer feasible. By 1985 such strains had been isolated in the United States". Resistance was due to a 25.2-megadalton plasmid 22 which was composed of a 24.5-MDa-transferplasmid and the s~eptoco~cus-tetMdete~ant. Some of the strains ISolated in the USA additionally had a penicillin-resistance plasmid-'.
Spectinomycin-resistant strains also became a cause for concern worldwidel". They tended to emerge in areas where spectinomycin was used on a large scale in the treatment of gonorrhoea". Spectinomycin resistance is chromosome mediated and usuallr not combined with plasmid mediated resistance 1 • As a consequence penicillin and tetracycline should no longer be used in the treatment of gonorrhoea. Spectinomycin is still recommended by some institutions, but there is a resistance problem in some areas. Thus there is now clearly a role for alternatives such as cephalosporins or quinolones.
REQUIREMENTS OF AN EFFECTIVE THERAPY FOR UNCOMPLICATED GONORRHOEA
A regimen used in the treatment of gonococcal infection should have the following characteristics:
The antibiotic used should have an excellent in vitro activity against all gonococci. In practice this means that the cure rates to be expected judging from MIC values and tissue levels in man should lie in the 95 to 100% range.
In order to reduce the selection of resistant strains the concentrations of the drug in the blood and other relevant tissues should at least exceed those required to inhibit at least the majority of comparatively resistant strains.
Furthermore, one-shot therapy with identical doses for male and female individuals should be possible.
International Journal of STD & AIDS Volume 5 July/August 1994 Last but not least, the regimen should not be linked to severe side effects, in particular there should virtually be no allergic side effects. At the moment we know 3 different types of resistance: resistance due to penicillinase production, other types of resistance due to plasmids and resistance which is mediated by chromosomes. Ideally, effective antibiotic therapy should be able to eradicate these 3 types of resistant strains 43 •
ONE-SHOT TREATMENT OF UNCOMPLICATED GONORRHOEA
In the sixties cephalosporins had already been established in the antibiotic treatment of various infectious diseases. Already first generation cephalosporins like cephalothin or cephaloridin showed a fairly good in vitro activity. Yet in the treatment of gonococcal infections with a single dose of 1 or 2" i.m, the cure rates amounted only to 50-84%28,2 . Moreover, severe anaphylactic reactions in patients with penicillin allergy were seen.
Second generation cephalosporins like cefazoline showed better pharmacokinetic properties but the cure rates by one time intramuscular injection of 1/ 2 or 3 g lay between 58% and 90%19,34. Furthermore, after the general use of primarily promising congeners like cefuroxime, strains rapidly spread which showed relatively less susceptibility in vitro and could not be eradicated with established treatment protocols'". A breakthrough, however, was obtained with the development of third generation cephalosporins.
Cefotaxime
In the early eighties, a single i.m, application of cefotaxime was established as a reliable treatment for uncomplicated disease. In vitro data demonstrated excellent activity against N. gonorrhoeailO. Cure rates based on doses of 0.5 to 2 g i.m. ranged from 93%_100%14,36. Yet the short half-life of cefotaxime (1.2 h) is regarded as a disadvantage by some, as it is linked to the need for comparatively hi~doses, Le., lor 2 g, to reach curative drug levels . In our series the high efficacy of a single intramuscular injection of a dose as low as 0.5 g could be proven, the cure rate in this comparative study was %.7%36.
MIC so and MI~values tested on isolates which
were obtained before treatment read 0.004 gil and 0.016 gil.
In 1989/ in the guidelines from the Centers for Disease Control cefotaxime was recommended together with ceftriaxone for the treatment of gonococcal disease",
Ceftriaxone
Ceftriaxone is another third generation cephalosporin. The substitution of an enolate anion in the triazine moiety leads to an extended serum half-life. Most third generation cephalosporins have a serum half-life ranging from O.9h to 2.8h s ,12. Various studies using In a Munich trial 250 mg of ceftriaxone were compared to 500 mg of cefotaxime. The MIC values of the isolates which were gained before treatment amounted to 0.002 gIl (MIC so ) and 0.004 gIl (MICxJ).
All patients treated with ceftriaxone were cured as were those put on cefotaxime except for one. Similar results were found in other studies 15 ,3. Table 1 shows the efficacy of ceftriaxone according to 3 separate trials.
In all of these, practically no severe side effects were found. Very few patients complained of local pain after injection. Some gastrointestinal side effects were observed. Recently one case of severe hypersensitivity reaction has been reportedv. In order to avoid local side effects, the antibiotic should be dissolved in local anaesthetic solution.
Cefixime
Cefixime is a new second generation oral cephalosporin with excellent activity against N. gonorrhoeae.
Apart from a single i.m. injection of ceftriaxone, many institutions and societies (including the Centers for Disease Control) recommend a single dose of oral cefixime. Orally administrable regimens are a good alternative in the treatment of uncomplicated gonorrhoea in injecting drug users to reduce needle usage. Moreover oral administration is more convenient than intramuscular injection. In a multicentre study by Handsfield and co-workersl" 400 and 800 mg of cefixime were compared to 250 mg of ceftriaxonein patients with uncomplicated gonorrhoea.
Generally speaking, single doses of 400 and 800 mg of cefixime have similar efficacy in the treatment of uncomplicated gonorrhoea. Cure rates exceed 95%. Similar results were found in various Table 2 . Minimal inhibitory concentrations offluoroquinolones to N. gonorrhoeae Cephalosporin therapy versus quinolone therapỹ d generation cephalosporins currently fulfil the cnteria previously discussed for the treatment other studies 26 ,31. Both doses of cefixime lead to plasma drug levels that exceed the highest MIC so far ported for N. gonorrhoeae, i.e., 0.25 g/l42. Cefixime 18 c~>nsidered safe for pregnant women and children, w~lch gives cefixime an advantage over oral 9,U1nolones. Another advantage of cefixime is that it IS cheaper than ceftriaxone. Currently a single dose of 400mg of cefixime is particularly recommended-''.
Fluoroquinolones in the treatment of uncomplicated gonorrhoea
I~the mid-eighties second generation quinolones like norfloxacin, ofloxacin and ciprofloxacin were developed. These have a broad antimicrobial spectr.um, a higher activity and slow development of reSistance, which is not plasmid mediated.
. Se~ond generation quinolones have been tested In tniro and in vivo. Ciprofloxacin, enoxacin and ofloxacin are commonly recommended in the treat~ent of gonococcal infection 7 ,8, but recent studies show, that also temafloxacin, fleroxacin, o~oxacin and lomefloxacin have good to excellent In vrtro activity against N. gonorrhoeae 43 • Table 2 shows the results of in vitro testing of various second gen~ration quinolones. CiprofJoxacin, which is often used as an alternative to third generation cephalosporins, achieves high concentrations in urethral and prostatic secretions.
. gonorrhoeae in vitro is highly susceptible against t 18 d~g33. Bryan and co-workers report on a study In Zambia where ciprofloxacin 250 mg orally Wastested versus ceftriaxone 250 mg i.m. The study Was conducted in an area with a high prevalence of penicillinase producing strains and strains with chromosomally-mediated resistance to tetracycline and penicillin 3 • Studies demonstrated a similar efficacy of single dose treatment with oral dprofloxacin COmfared with a single intramuscular injection of c~ftrlaxone. This was confirmed by other studies'. Side-effects of ciprofloxacin are quite rare, therefore the acceptability is high. Ofloxacin also has a broad spectrum of activity against Gram positive and Gram negative bacteria. In vitro and in vivotesting showed that ofloxacin in particular has a very good activity against N. gonorrhoeae. Cure rates range up to 100%38. of uncomplicated gonorrhoea. Cefotaxime and ceftriaxone as well as cefixime reach bacteriological cure rates near to 100%, even in the presence of penicillinase producing strains. The association of higher MICs with penicillin resistance has not been a problem in practice, because maximal MICs are still well within the concentrations reached in man'". Concern that in the nearer future chromosomally mediated resistance would develop was not justified! Single dose treatment is very effective, and the same doses can be used in the treatment of males and females. Furthermore, third generation cephalo- As an alternative, second generation quinolones can be used in the treatment of uncomplicated gonorrhoea. Ofloxacin and ciprofloxacin show especially good serum and tissue levels 44 • FIuoroquinolones should be the first therapeutic choice, in case there is a hypersensitivity to penicillin or cephalosporins. Furthermore orally administered drugs are preferable in third world countries with a high prevalence of HIV, in order to prevent infection via poorly sterilized needles. FIuoroquinolones should not be used in the treatment of pregnant women and children, as side effects can be severe. After quinolone therapy damage of cartilage in the fetus and in young children has been observed. If pregnant women or children are to be cured by an orally administrable regimen, cefixime is considered to be effective and safe 37 
